InVivo Therapeutics (NSDQ:NVIV) said today that a patient enrolled in December in its Inspire study has improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury. This is the 6th patient from the 11-patient group to have an AIS grade improvement at the 1-month follow-up mark.
The Cambridge, Mass.-based company also noted that 2 patients who have not converted yet are early in follow-up and could see an AIS grade improvement before the 6-month endpoint.
The trial’s 54.5% conversation rate is higher than rates observed in a range of spinal cord injury natural history databases, InVivo reported.
“I have been encouraged by the data generated to date in the Inspire study, including the 2 conversions in patients that I have implanted with the neuro-spinal scaffold.” Dr. Domagoj Coric, chief of neurosurgery at the Carolinas Medical Center, said in prepared remarks.
“The AIS conversion rate observed thus far in the Inspire study has exceeded expectations,” CEO & chairman Mark Perrin added. “We look forward to following this patient’s progress, and we’re hopeful that we will continue to observe positive Inspire results as we work towards completing enrollment.”
This week, Medford, Mass.-based PixarBio (OTC:PXRB) withdrew a bizarre, $100 million takeover bid for InVivo, the company that PixarBio CEO Frank Reynolds’ co-founded. PixarBio said it plans to “stay focused on our NeuroRelease pain platform and continue to drive our non-opiate non addictive [sic] morphine replacement to market with FDA approval expected between the end of 2018 and early 2019.”
InVivo also said this month that it added an 11th patient and a new clinical site to its Inspire study. The University of New Mexico Hospital marks the 30th clinical site participating in InVivo’s trial.
NVIV shares were trading at $4.70 in mid-morning activity, up 11.9%.